Hoarau E, Quilhot P, Baaroun V, Lescaille G, Campana F, Lan R, Rochefort J
Service Odontologie, Assistance Publique Hôpitaux de Paris (AP-HP), La Pitié-Salpêtrière, Paris, France.
Aix Marseille Univ, APHM, Timone Hospital, Oral Surgery Department, Marseille, France.
Heliyon. 2023 Feb 25;9(3):e14087. doi: 10.1016/j.heliyon.2023.e14087. eCollection 2023 Mar.
The distinction between giant cell tumors and giant cell granulomas is challenging, as both entities have overlapping diagnostic criteria, especially in oral locations. The two entities have similar clinical and radiological presentations, but they differ in their prognoses.
The main objective of this study was to list the clinical, radiological, histological, and prognostic features of maxillomandibular giant cell tumors and giant cell granulomas cases n order to assess their value as a diagnostic referral factor that may allow the distinction between maxillo-mandibular giant cell granuloma and giant cell tumor.
Data of maxillomandibular giant cell granulomas and giant cell tumors were assessed through a scoping review and a pre-existing systematic review of literature. We have also realized a bicentric retrospective study.
Various criteria facilitate the differential diagnosis like age, size, locularity and presence of necrosis zone but not the gender. The most discriminating factors was symptomatology (reported in 72% of GCTs while only 15% of GCGs) and the distribution pattern of giant cells in the stroma (homogeneously dispersed in 80% of GCTs versus grouped in clusters in 86.7% of GCGs). Recurrences were most described for giant cell tumors than giant cell granulomas. Malignant transformation and pulmonary metastasis were exclusively reported for giant cell tumors.
As clinical and radiological elements are not sufficient to distinguish between these two entities, immunohistochemistry and molecular genetics can be represent diagnostic biomarkers to distinguish giant cell granulomas and giant cell tumors in oral cavity. We have attempted to define the main criteria for the differentiation of giant cell tumor and giant cell granuloma and propose a decision tree for the management of single maxillomandibular giant cell lesions.
巨细胞瘤和巨细胞肉芽肿的区分具有挑战性,因为这两种病变的诊断标准存在重叠,尤其是在口腔部位。这两种病变具有相似的临床和放射学表现,但预后不同。
本研究的主要目的是列出颌骨巨细胞瘤和巨细胞肉芽肿病例的临床、放射学、组织学和预后特征,以评估其作为诊断参考因素的价值,从而有助于区分颌骨巨细胞肉芽肿和巨细胞瘤。
通过范围综述和对现有文献的系统综述,评估颌骨巨细胞肉芽肿和巨细胞瘤的数据。我们还开展了一项双中心回顾性研究。
多种标准有助于鉴别诊断,如年龄、大小、分叶情况和坏死区的存在,但性别因素无鉴别意义。最具鉴别力的因素是症状(72%的巨细胞瘤有症状,而巨细胞肉芽肿仅有15%有症状)以及巨细胞在基质中的分布模式(80%的巨细胞瘤中巨细胞均匀分散,而86.7%的巨细胞肉芽肿中巨细胞成簇聚集)。巨细胞瘤的复发报道多于巨细胞肉芽肿。恶性转化和肺转移仅见于巨细胞瘤。
由于临床和放射学因素不足以区分这两种病变,免疫组织化学和分子遗传学可作为诊断生物标志物,用于区分口腔中的巨细胞肉芽肿和巨细胞瘤。我们试图确定巨细胞瘤和巨细胞肉芽肿鉴别的主要标准,并提出一个用于管理单个颌骨巨细胞病变的决策树。